



A convenient synthesis of furo[3,2-*c*]coumarins by a tandem alkylation/intramolecular aldolisation reaction

Francesco Risitano,* Giovanni Grassi, Francesco Foti and Cristina Bilardo

Dipartimento di Chimica Organica e Biologica, Università, Vill. S. Agata, I-98166 Messina, Italy

Received 12 January 2001; revised 12 March 2001; accepted 21 March 2001


Abstract—A simple and efficient synthesis of furo[3,2-*c*]coumarin derivatives from 4-hydroxycoumarin and α -haloketones via a tandem *O*-alkylation/cyclisation protocol is described. © 2001 Elsevier Science Ltd. All rights reserved.

The 4-hydroxycoumarin fragment occurs in many synthetic and natural products, which are used clinically as drugs and pesticides¹ as well as oral anticoagulants² and rodenticides.³ These important applications have generated considerable interest in this ring system and various 2,3- or 3,4-fused polycycles or open chain derivatives have been synthesised. While many efforts have been made to synthesise 3-alkyl-4-hydroxycoumarin derivatives,⁴ only a few studies have focussed on the synthesis of linearly or angularly fused tricyclic complex systems. All the reported procedures referring to this particular system require vigorous reaction conditions and laborious preparation.⁵

This paper describes a simple and easy route to new angular furocoumarins **3** differentially substituted on

the five-membered ring, starting from 4-hydroxycoumarin **1**. The reaction is also interesting because the framework of these systems is entirely present in the coumestans (6*H*-benzofuro[3,2-*c*]benzopyran-6-ones), a class of physiologically active natural compounds such as wedelolactone, medicagol, psoralidin, isopsoralidin, erosnin, and many others.⁶

The idea arose from the observation that the highly reactive enolic moiety of **1** can easily be utilised, together with selected building blocks, in the construction of angular or linear polyheterocycles. With this in mind, we chose the double electrophile α -haloketones **2** (Scheme 1). In fact, for the entries (a–e), treatment of **1** with the ambident reagents **2** produced the expected cycloadducts **3** in good yield (70–77%).⁷ The reaction



Scheme 1.

* Corresponding author. Tel.: +390906765512; fax: +39 90 393897; e-mail: frisitan@isengard.unime.it


was carried out in glacial AcOH/AcONH₄ or piperidine in refluxing toluene/EtOH (4:1). In entry **f**, the desired cycloaddition failed: desyl chloride **2f** and **1** were recovered unreacted. This failure can be attributed to the presence of the bulky phenyl substituent in the α -position. In entry **g**, however, the reaction of **1** with **2g** under similar conditions (AcOH/AcONH₄, refluxing toluene/EtOH) gave the dihydrofuran derivative **4** in high yield (90%).⁷ It must be noted that chemoselective cyclisation is favoured at the carbonyl-C, rather than at the ester-C, in accordance with accepted rules.⁸ The stability of the α -hydroxyester **4** is remarkable and it can be recrystallised and stored without any decomposition. Moreover, it cannot be converted into the corresponding derivative **3g**. Treatment of the isolated **4** with acids or bases did not promote any dehydration and, at the end, compound **4** was unaltered.

All the compounds synthesised were characterised by their ¹H and ¹³C NMR, and IR spectra, as well as by elemental analyses.⁹ IR spectra of compounds **3a–e** and **4** contain bands at 1735–1755 cm⁻¹ which are characteristic of the stretching vibrations of the coumarin carbonyl group. For compound **4** C=O_{ester} and OH bands were also observed at 1702 cm⁻¹ and at 3331 cm⁻¹, respectively. In the ¹H NMR spectrum of the dihydro derivative **4** the signal related to the OH appears at δ 6.54 and exchanges with D₂O; the methylene protons are split into an AB quartet centred at δ

4.90 due to the generation of a new chiral carbon. An X-ray crystallographic analysis carried out on **3b** also confirmed the structure of compounds **3**.¹⁰

Formation of **3** can proceed following two different pathways (Scheme 2). Firstly, (i), through dehydration of **6** obtained by intramolecular C–C bond formation of the initial adduct **5**. Alternatively, (ii), by the tautomeric form **7B** of the aldol product **7A**, which is subjected to a 5-*exo-trig* cyclisation to give **6** through intramolecular O–C bond formation and dehydration, in a manner which follows the well-known Feist–Benary synthesis¹¹ of 3-carbonyl substituted furans. The latter reaction pathway also implies a partial change in the direction of cyclisation. A similar process should occur, at least partially, for the tautomeric form **7C** through the lactone carbonyl oxygen to give linear polycyclic fused heterocycles such as **8** or **9**.

The existence of the 4-hydroxycoumarin/2-hydroxychromone tautomerism¹² has been demonstrated, for instance, by the treatment of 4-hydroxycoumarin with diazomethane, which afforded a mixture of 4-methoxycoumarin and 2-methoxychromone.¹³ Since products **8** and **9** were not observed, it can be assumed that **3** is formed through pathway (i). In confirmation of this, the X-ray of 3-phenylfuro[3,2-*c*]coumarin **3b** showed the phenyl substituent exclusively in the 3-position.¹⁰



Scheme 2.

On the basis of the above results, the reaction leading to **3** is unhindered when the nearby α -carbon of **2** is not particularly bulky. This can prevent the *O*-alkylation process and/or the following 5-*exo-trig* cyclisation. When this condition is satisfied, the resulting hydroxyl group on the tertiary carbon atom or in the benzylic position is easily expelled as water, under the conditions used, to give **3**. The unsuccessful dehydration of **4** to give **3g**, however, reflects the well-known difficulties that α -hydroxy-acids or -esters have in losing water intramolecularly.

References

- (a) Feuer, G. *Prog. Med. Chem.* **1973**, *10*, 85–93; (b) Obaseki, O.; Porter, W. R. *J. Heterocyclic Chem.* **1982**, *19*, 385–390; (c) Das Gupta, K.; Chatterjee, R. M.; Das, K. R. *Indian J. Chem. Sect. B* **1981**, *20*, 511–515.
- (a) Kazmier, F. J. *Mayo Clin. Proceed.* **1974**, *49*, 918–925; (b) Kralt, T.; Classen, V. In *Drug Design*; Ariens, E. J., Ed.; Academic Press: New York, 1972; Vol. 3, pp. 189–230; (c) O'Reilly, R. A. *Ann. Rev. Med.* **1976**, *27*, 245–262.
- Hermodson, M. A.; Barker, W. M.; Link, K. P. *J. Med. Chem.* **1971**, *14*, 167–173.
- Appendino, G.; Cravotto, G.; Tagliapietra, S.; Ferraro, S.; Nano, G. M.; Palmisano, G. *Helv. Chim. Acta* **1991**, *74*, 1451–1458 and references cited therein.
- (a) Saidi, M. R.; Bigdeli, K. *J. Chem. Res. (S)* **1998**, 800–801 and references cited therein; (b) Majumdar, K. C.; De, R. N.; Khan, A. T.; Chattopdhyay, S. K.; Dey, K.; Patra, A. *J. Chem. Soc., Chem. Commun.* **1988**, 777–779; (c) Yakout, E. M. A.; Ibrahim, N. M.; Ghoneim, K. M.; Mahran, M. R. H. *J. Chem. Research (S)* **1999**, 652–653; (d) Appendino, G.; Cravotto, G.; Palmisano, G.; Annunziata, R. *Synth. Commun.* **1996**, *26*, 3359–3371; (e) Appendino, G.; Cravotto, G.; Toma, L.; Annunziata, R.; Palmisano, G. *J. Org. Chem.* **1994**, *59*, 5556–5564; (f) Girreser, U.; Heber, D.; Schutt, M. *J. Heterocycl. Chem.* **1998**, *35*, 1455–1460; (g) Kappe, T.; Mayer, C. *Synthesis* **1981**, 524–526.
- (a) Wong, E. *Fortschr. Chem. Org. Naturst.* **1970**, *28*, 1–152; (b) Bickoff, E. M.; Livingston, A. L.; Booth, A. N.; Thompson, C. R.; Hollwell, E. A.; Beinhart, E. G. *J. Anim. Sci.* **1960**, *19*, 4–12; (c) Darbarwar, M.; Sundaramurthy, V.; Subba Rao, N. V. *Indian J. Chem.* **1973**, *11*, 115–118.
- A typical experimental procedure for the preparation of **3** and **4**. A toluene solution of the appropriate α -haloketone **2** (4 mmol) was added to a solution of 4-hydroxycoumarin **1** (0.65 g, 4 mmol) and AcOH/AcONH₄ (20 mmol) in toluene/EtOH abs. (50 ml; 40:10). The mixture was stirred for 1 h and the solvent evaporated under reduced pressure. The oily residue was treated with cold water (30 ml) and the precipitate was filtered off, washed with water (50 ml) and recrystallised from EtOH to give **3a–e** or **4**.
- (a) Baldwin, J. E. *J. Chem. Soc., Chem. Commun.* **1976**, 734736; (b) Baldwin, J. E.; Cutting, J.; Dupont, W.; Kruse, L.; Silbermann, L.; Thomas, R. C. *J. Chem. Soc., Chem. Commun.* **1976**, 736–738; (c) Baldwin, J. E.; Reiss, J. A. *J. Chem. Soc., Chem. Commun.* **1977**, 77.
- Selected data: **3a**: mp 135°C; IR (Nujol): $\nu=1747$ cm⁻¹; ¹H NMR (CDCl₃, 300 Mz, rt): $\delta=2.30$ (s, 3H, CH₃), 7.24–7.82 (m, 5H); ¹³C NMR (CDCl₃, 75 Mz, rt): $\delta=8.2, 102.1, 112.5, 116.8, 119.6, 120.5, 124.6, 130.1, 142.5, 151.8, 156.9, 158.2$. Anal. C₁₂H₈O₃ requires (%) C, 72.88; H, 4.03. Found (%) C, 73.08; H, 4.12. Compound **3b**: mp 177°C; IR (Nujol): $\nu=1739$ cm⁻¹; ¹H NMR (CDCl₃, 300 Mz, rt): $\delta=7.35$ –7.89 (m, 10H); ¹³C NMR (CDCl₃, 75 Mz, rt): $\delta=107.8, 110.6, 112.1, 120.1, 124.8, 125.3, 128.0, 128.3, 128.5, 129.0, 131.3, 143.3, 151.9, 157.0, 158.1$. Anal. C₁₇H₁₀O₃ requires (%) C, 77.85; H, 3.84. Found (%) C, 77.98; H, 3.92. Compound **3c**: mp 198°C; IR (Nujol): $\nu=1747$ cm⁻¹; ¹H NMR (CDCl₃, 300 Mz, rt): $\delta=7.33$ –7.91 (m, 9H); ¹³C NMR (CDCl₃, 75 Mz, rt): 107.7, 112.0, 116.1, 120.8, 121.3, 121.5, 124.2, 124.9, 128.4, 130.5, 131.4, 143.4, 152.0, 157.2, 158.2. Anal. C₁₇H₉BrO₃ requires (%) C, 59.85; H, 2.66. Found (%) C, 60.08; H, 2.82. Compound **3d**: mp 166°C; IR (Nujol): $\nu=1740$ cm⁻¹; ¹H NMR (CDCl₃, 300 Mz, rt): $\delta=3.88$ (s, 3H, OCH₃), 6.98–7.87 (m, 9H); ¹³C NMR (CDCl₃, 75 Mz, rt): $\delta=54.7, 107.1, 112.3, 114.7, 121.3, 121.6, 124.3, 125.0, 128.4, 130.6, 131.3, 143.3, 152.0, 157.5, 158.2, 160.9$. Anal. C₁₈H₁₂O₄ requires (%) C, 73.97; H, 4.14. Found (%) C, 74.08; H, 4.21. Compound **3e**: mp 150°C; IR (Nujol): $\nu=1735$ cm⁻¹; ¹H NMR (CDCl₃, 300 Mz, rt): $\delta=2.50$ (s, 3H, CH₃), 7.30–7.85 (m, 9H); ¹³C NMR (CDCl₃, 75 Mz, rt): $\delta=12.8, 107.8, 112.4, 116.5, 120.4, 124.5, 127.8, 128.4, 129.5, 130.8, 143.8, 149.4, 152.0, 153.2, 157.0, 158.1$. Anal. C₁₂H₈O₃ requires (%) C, 78.25; H, 4.38. Found (%) C, 78.48; H, 4.50. Compound **4**: mp 134°C; IR (Nujol): $\nu=1755, 1702$ cm⁻¹; ¹H NMR (DMSO-d₆, 300 Mz, rt): $\delta=1.11$ (t, 3H, CH₃, *J*=7.1 Hz), 4.20 (q, 2H, OCH₂, *J*=7.1 Hz), 4.90 (ABq, 2H, CH₂ring, *J*=10.7 Hz), 6.54 (s, 1H, OH), 7.41–7.81 (m, 4H); ¹³C NMR (DMSO-d₆, 75 Mz, rt): $\delta=14.8, 61.9, 79.8, 86.1, 106.5, 111.74, 117.1, 123.4, 124.9, 134.7, 155.0, 157.6, 167.9, 170.7$. Anal. C₁₄H₁₂O₆ requires (%) C, 60.87; H, 4.38. Found (%) C, 61.08; H, 4.52.
- Bruno, G.; Nicolò, F.; Rotondo, A.; Risitano, F.; Grassi, G.; Foti, F.; Bilardo, C. *Acta Crystallogr., Sect. C*, in press.
- (a) Feist, F. *Chem. Ber.* **1902**, *35*, 1545; (b) Benary, E. *Chem. Ber.* **1911**, *44*, 493–499.
- Porter, W. R.; Trager, W. F. *J. Heterocyclic Chem.* **1982**, *19*, 475–480 and references cited therein.
- Arndt, F.; Loewe, L.; Un, R.; Ayca, E. *Chem. Ber.* **1951**, *84*, 319–325.